Key facts
- It has raised $27.0M; the latest was Seed Round ($27.0M) in Dec 2025.
- Notable investors include Golden Falcon Capital.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for SubSense
- ·The full record, as it builds
Funding rounds
No funding rounds for SubSense are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SubSense
Developer of biocompatible nanoparticles intended for tracking brain activity. The company's devices help with paralysis and neurological disorders, treating neurological and neurodegenerative diseases, human-machine interactions machine and bidirectional brain-computer interface, enabling the healthcare sector to improve lives and redefine the interaction between human cognition and technology.
- Sector
- Healthcare
- HQ
- Covina, CA, United States
- Founded
- 2022
- Employees
- 9
- Website
- subsense-bci.com/
- Ownership
- Privately Held (backing)
SubSense doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SubSense shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SubSense in its N-PORT filings yet. We sweep new filings monthly.